Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone.
Ryan CJ, Rosenthal M, Ng S, Alumkal J, Picus J, Gravis G, Fizazi K, Forget F, Machiels JP, Srinivas S, Zhu M, Tang R, Oliner KS, Jiang Y, Loh E, Dubey S, Gerritsen WR. Ryan CJ, et al. Among authors: alumkal j. Clin Cancer Res. 2013 Jan 1;19(1):215-24. doi: 10.1158/1078-0432.CCR-12-2605. Epub 2012 Nov 7. Clin Cancer Res. 2013. PMID: 23136195 Clinical Trial.
LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function.
Kumaraswamy A, Duan Z, Flores D, Zhang C, Sehrawat A, Hu YM, Swaim OA, Rodansky E, Storck WK, Kuleape JA, Bedi K, Mannan R, Wang XM, Udager A, Ravikumar V, Bankhead A 3rd, Coleman I, Lee JK, Morrissey C, Nelson PS, Chinnaiyan AM, Rao A, Xia Z, Yates JA, Alumkal JJ. Kumaraswamy A, et al. Among authors: alumkal jj. JCI Insight. 2023 Aug 8;8(15):e167440. doi: 10.1172/jci.insight.167440. JCI Insight. 2023. PMID: 37440313 Free PMC article.
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.
Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, Scher HI, Chin K, Gagnier P, McHenry MB, Beer TM. Slovin SF, et al. Among authors: alumkal jj. Ann Oncol. 2013 Jul;24(7):1813-1821. doi: 10.1093/annonc/mdt107. Epub 2013 Mar 27. Ann Oncol. 2013. PMID: 23535954 Free PMC article. Clinical Trial.
Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer.
Hussain M, Carducci MA, Slovin S, Cetnar J, Qian J, McKeegan EM, Refici-Buhr M, Chyla B, Shepherd SP, Giranda VL, Alumkal JJ. Hussain M, et al. Among authors: alumkal jj. Invest New Drugs. 2014 Oct;32(5):904-12. doi: 10.1007/s10637-014-0099-0. Epub 2014 Apr 26. Invest New Drugs. 2014. PMID: 24764124 Free PMC article. Clinical Trial.
Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen.
Hussain M, Corn PG, Michaelson MD, Hammers HJ, Alumkal JJ, Ryan CJ, Bruce JY, Moran S, Lee SY, Lin HM, George DJ; Prostate Cancer Clinical Trials Consortium, a program of the Department of Defense Prostate Cancer Research Program and the Prostate Cancer Foundation. Hussain M, et al. Among authors: alumkal jj. Clin Cancer Res. 2014 Aug 15;20(16):4218-27. doi: 10.1158/1078-0432.CCR-14-0356. Epub 2014 Jun 25. Clin Cancer Res. 2014. PMID: 24965748 Clinical Trial.
Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.
Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, Lin AM, Alumkal J, Graff JN, Nordquist LT, Herrera I, Small EJ. Aggarwal RR, et al. Among authors: alumkal j. Clin Genitourin Cancer. 2015 Jun;13(3):e191-8. doi: 10.1016/j.clgc.2014.12.004. Epub 2014 Dec 9. Clin Genitourin Cancer. 2015. PMID: 25557266 Clinical Trial.
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, Alumkal JJ, Higano CS, Chow Maneval E, Bandekar R, de Boer CJ, Yu MK, Rathkopf DE. Smith MR, et al. Among authors: alumkal jj. Eur Urol. 2016 Dec;70(6):963-970. doi: 10.1016/j.eururo.2016.04.023. Epub 2016 May 6. Eur Urol. 2016. PMID: 27160947 Free PMC article. Clinical Trial.
Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone.
Rathkopf DE, Antonarakis ES, Shore ND, Tutrone RF, Alumkal JJ, Ryan CJ, Saleh M, Hauke RJ, Bandekar R, Maneval EC, de Boer CJ, Yu MK, Scher HI. Rathkopf DE, et al. Among authors: alumkal jj. Clin Cancer Res. 2017 Jul 15;23(14):3544-3551. doi: 10.1158/1078-0432.CCR-16-2509. Epub 2017 Feb 17. Clin Cancer Res. 2017. PMID: 28213364 Free PMC article. Clinical Trial.
Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial.
Alumkal JJ, Chowdhury S, Loriot Y, Sternberg CN, de Bono JS, Tombal B, Carles J, Flaig TW, Dorff TB, Phung D, Forer D, Noonberg SB, Mansbach H, Beer TM, Higano CS. Alumkal JJ, et al. Clin Genitourin Cancer. 2017 Oct;15(5):610-617.e3. doi: 10.1016/j.clgc.2017.02.007. Epub 2017 Mar 3. Clin Genitourin Cancer. 2017. PMID: 28344102 Clinical Trial.
104 results